Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.

MLA

Kulasekararaj, Austin G., et al. “Ravulizumab (ALXN1210) vs Eculizumab in C5-Inhibitor-Experienced Adult Patients with PNH: The 302 Study.” Blood, vol. 133, no. 6, Feb. 2019, pp. 540–49. EBSCOhost, https://doi.org/10.1182/blood-2018-09-876805.

APA

Kulasekararaj, A. G., Hill, A., Rottinghaus, S. T., Langemeijer, S., Wells, R., Gonzalez-Fernandez, F. A., Gaya, A., Lee, J. W., Gutierrez, E. O., Piatek, C. I., Szer, J., Risitano, A., Nakao, S., Bachman, E., Shafner, L., Damokosh, A. I., Ortiz, S., Röth, A., & Peffault de Latour, R. (2019). Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood, 133(6), 540–549. https://doi.org/10.1182/blood-2018-09-876805

Chicago

Kulasekararaj, Austin G, Anita Hill, Scott T Rottinghaus, Saskia Langemeijer, Richard Wells, F Ataulfo Gonzalez-Fernandez, Anna Gaya, et al. 2019. “Ravulizumab (ALXN1210) vs Eculizumab in C5-Inhibitor-Experienced Adult Patients with PNH: The 302 Study.” Blood 133 (6): 540–49. doi:10.1182/blood-2018-09-876805.